SG11202008098TA - Antibody-based methods of detecting and treating alzheimer's disease - Google Patents

Antibody-based methods of detecting and treating alzheimer's disease

Info

Publication number
SG11202008098TA
SG11202008098TA SG11202008098TA SG11202008098TA SG11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA SG 11202008098T A SG11202008098T A SG 11202008098TA
Authority
SG
Singapore
Prior art keywords
antibody
disease
detecting
based methods
treating alzheimer
Prior art date
Application number
SG11202008098TA
Inventor
Jozef Hanes
Eva Kontsekova
Andrej Kovac
Norbert Zilka
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of SG11202008098TA publication Critical patent/SG11202008098TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202008098TA 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease SG11202008098TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US201862703299P 2018-07-25 2018-07-25
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Publications (1)

Publication Number Publication Date
SG11202008098TA true SG11202008098TA (en) 2020-10-29

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008098TA SG11202008098TA (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Country Status (12)

Country Link
EP (1) EP3774887A2 (en)
JP (1) JP2021520777A (en)
KR (1) KR20200144551A (en)
CN (1) CN112236452A (en)
AU (1) AU2019244481A1 (en)
BR (1) BR112020018868A2 (en)
CA (1) CA3095443A1 (en)
IL (1) IL277577A (en)
MX (1) MX2020009991A (en)
RU (1) RU2020135052A (en)
SG (1) SG11202008098TA (en)
WO (1) WO2019186276A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
JP7170316B2 (en) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド Tau immunotherapy
KR102471787B1 (en) 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 Tau recognition antibody
IL270375B1 (en) 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies recognizing tau
CU20210073A7 (en) 2019-03-03 2022-04-07 Prothena Biosciences Ltd ANTIBODIES THAT BIND WITHIN THE CDRS-DEFINED MICROTUBULE-BINDING REGION OF TAU
AU2020345110A1 (en) 2019-09-09 2022-03-24 Axon Neuroscience Se Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
CN117043183A (en) * 2020-12-16 2023-11-10 沃雅戈治疗公司 TAU binding compounds
JP2024509683A (en) * 2021-02-19 2024-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-PT217 TAU antibody
CN117003863A (en) * 2022-04-28 2023-11-07 厦门大学 Antibodies to p-tau 217 and uses thereof
CN114778856B (en) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 Phosphorylated tau protein detection kit
WO2024040212A2 (en) * 2022-08-19 2024-02-22 Staidson Biopharma Inc. Antibodies specifically recognizing programmed cell death 1 ligand 1 and uses thereof
CN117624351B (en) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 Anti-human phosphorylated tau181 rabbit monoclonal antibody and application thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2141216A1 (en) 1992-07-27 1994-02-03 Michael J. Micklus Targeting of liposomes to the blood-brain barrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (en) 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
WO1997004801A1 (en) 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
ATE234635T1 (en) 1995-12-22 2003-04-15 Bristol Myers Squibb Co COUPLERS CONTAINING BRANCHED HYDRAZONE GROUPS
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (en) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
ATE391781T1 (en) 2002-07-12 2008-04-15 Axon Neuroscience TRANSGENIC ANIMAL WHICH EXPRESSES THE TRUNKED ALZHEIMER TAU PROTEIN
KR101186210B1 (en) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
CA2511599A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
US8613924B2 (en) * 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
NZ626269A (en) * 2011-12-20 2016-06-24 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SI3221349T1 (en) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
US20190315886A1 (en) * 2016-02-05 2019-10-17 Jiangsu Hengrui Medicine Co., Ltd. Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof

Also Published As

Publication number Publication date
CN112236452A (en) 2021-01-15
WO2019186276A2 (en) 2019-10-03
AU2019244481A1 (en) 2020-10-01
MX2020009991A (en) 2020-10-14
IL277577A (en) 2020-11-30
BR112020018868A2 (en) 2021-01-26
WO2019186276A8 (en) 2020-10-15
EP3774887A2 (en) 2021-02-17
WO2019186276A3 (en) 2020-02-27
JP2021520777A (en) 2021-08-26
RU2020135052A (en) 2022-04-29
CA3095443A1 (en) 2019-10-03
KR20200144551A (en) 2020-12-29

Similar Documents

Publication Publication Date Title
IL277577A (en) Antibody-based methods of detecting and treating alzheimer's disease
IL254030B (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease
IL247085B (en) Methods of treating alzheimer's disease
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
IL263433A (en) Methods for treating alzheimer's disease
IL246999B (en) Methods of treating alzheimer's disease
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
EP3458036A4 (en) Methods of treating or preventing alzheimer's disease and associated conditions
EP3377118A4 (en) Methods for treating alzheimer's disease and related disorders
IL288894A (en) Methods for evaluation and treatment of alzheimer's disease and applications thereof
IL276896A (en) Methods of treating crohn's disease with anti-il23 specific antibody
EP3558340A4 (en) Methods of using gm6 in diagnosing and treating alzheimer's disease
MA45865A (en) METHODS FOR DETECTION AND TREATMENT OF A TUMOR EXPRESSING PT346 PDK1
IL277182A (en) Compositions and methods for treating parkinson's disease
EP3347486A4 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
IL281395A (en) Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
EP3490546A4 (en) Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment
EP3773500A4 (en) Compositions and methods of detecting and treating alzheimer's disease
IL248935A0 (en) Diagnostic test and treatment/prevention of alzheimer's disease
EP3137097C0 (en) Treatment and prevention of alzheimer's disease (ad)
PL3137094T3 (en) Treatment and prevention of alzheimer's disease (ad)
PT3137093T (en) Treatment and prevention of alzheimer's disease (ad)
SG11202101274XA (en) Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease
IL265656A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease